About
Company Overview
Leadership Team
Board of Directors
Global Presence
Clinical Technology & Ecosystem
AI Principles
ESG
Participating in Clinical Trials
Therapeutics
Therapeutic Expertise
Oncology & Hematology
Cardiovascular-Metabolic
Rare Disease
Pediatrics
Gastroenterology
Nephrology
Dermatology
Ophthalmology
Cell & Gene Therapy
Neurology
Immunology
Infectious Disease
Clinical
Clinical Development Strategy
Early Phase Development
Phase II/III
Regulatory Strategy
Medical Affairs
Post-Marketing Solutions
Clinical Trial Delivery
Clinical Operations
Study Start-Up
Trial Feasibility
Project Management
RBQM
Medical Monitoring
Clinical Data Management
Biometrics
Medical Writing
Regulatory Services
Pharmacovigilance
Quality Assurance
Service Models
Resources
Resource Center
Blog
News
Events
Careers
Contact Us
About
Company Overview
Leadership Team
Board of Directors
Global Presence
Clinical Technology & Ecosystem
AI Principles
ESG
Participating in Clinical Trials
Therapeutics
Therapeutic Expertise
Oncology & Hematology
Cardiovascular-Metabolic
Rare Disease
Pediatrics
Gastroenterology
Nephrology
Dermatology
Ophthalmology
Cell & Gene Therapy
Neurology
Immunology
Infectious Disease
Clinical
Clinical Development Strategy
Early Phase Development
Phase II/III
Regulatory Strategy
Medical Affairs
Post-Marketing Solutions
Clinical Trial Delivery
Clinical Operations
Study Start-Up
Trial Feasibility
Project Management
RBQM
Medical Monitoring
Clinical Data Management
Biometrics
Medical Writing
Regulatory Services
Pharmacovigilance
Quality Assurance
Service Models
Resources
Resource Center
Blog
News
Events
Careers
Contact Us
Contact Us
About
Company Overview
Leadership Team
Board of Directors
Global Presence
Clinical Technology & Ecosystem
AI Principles
ESG
Participating in Clinical Trials
Therapeutics
Therapeutic Expertise
Oncology & Hematology
Cardiovascular-Metabolic
Rare Disease
Pediatrics
Gastroenterology
Nephrology
Dermatology
Ophthalmology
Cell & Gene Therapy
Neurology
Immunology
Infectious Disease
Clinical
Clinical Development Strategy
Early Phase Development
Phase II/III
Regulatory Strategy
Medical Affairs
Post-Marketing Solutions
Clinical Trial Delivery
Clinical Operations
Study Start-Up
Trial Feasibility
Project Management
RBQM
Medical Monitoring
Clinical Data Management
Biometrics
Medical Writing
Regulatory Services
Pharmacovigilance
Quality Assurance
Service Models
Resources
Resource Center
Blog
News
Events
Careers
Contact Us
About
Company Overview
Leadership Team
Board of Directors
Global Presence
Clinical Technology & Ecosystem
AI Principles
ESG
Participating in Clinical Trials
Therapeutics
Therapeutic Expertise
Oncology & Hematology
Cardiovascular-Metabolic
Rare Disease
Pediatrics
Gastroenterology
Nephrology
Dermatology
Ophthalmology
Cell & Gene Therapy
Neurology
Immunology
Infectious Disease
Clinical
Clinical Development Strategy
Early Phase Development
Phase II/III
Regulatory Strategy
Medical Affairs
Post-Marketing Solutions
Clinical Trial Delivery
Clinical Operations
Study Start-Up
Trial Feasibility
Project Management
RBQM
Medical Monitoring
Clinical Data Management
Biometrics
Medical Writing
Regulatory Services
Pharmacovigilance
Quality Assurance
Service Models
Resources
Resource Center
Blog
News
Events
Careers
Contact Us
Contact Us
Explore Our Latest News
and Press Releases
February 2026
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development
February 2026
Caidya Strengthens European Growth Strategy and Appoints Mario Bautista as Head of Business Development, Europe
December 2025
Caidya’s Miles Pan Named to Legal 500 GC Powerlist China 2025
November 2025
Caidya Reimagines Next Generation Clinical Trial Innovation and Study Delivery with Medidata AI-Powered Experiences
September 2025
Caidya Appoints Dr. Bin Peng as Chair of its China Scientific Advisory Board
July 2025
Caidya’s John Wang Named Chair of China CDISC Coordinating Committee; Medidata Accreditation Underscores Data Management Excellence
March 2025
Caidya Strengthens Therapeutic Leadership: Names Adam Callahan Head of Oncology and Hematology
January 2025
Caidya Names Brandon Pallott as CCO to Drive Innovative Commercial Initiatives and Market Expansion
January 2025
Caidya Announces $165 Million Strategic Growth Investment from Rubicon Founders
July 2024
Caidya Announces Leadership Transition: Barbara Lopez Kunz Named CEO
June 2024
Caidya Achieves Medidata Rave TSDV Accreditation, Enhancing Clinical Trial Efficiency and Data Integrity
April 2024
Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto
January 2024
Caidya Welcomes Jay Roberts to its Board of Directors
July 2023
Caidya Wins CRO Leadership Award for Overall Capabilities
November 2022
Caidya Announces Appointment of Barbara Lopez Kunz to Board of Directors
October 2022
Clinipace Name Change: Introducing Caidya, a New Name for a Leading Global CRO
April 2021
CROs dMed and Clinipace merge to accelerate customer success